Dipeptidyl peptidase-4 inhibitors (DPP-4is) and glucagon-like peptide- 1 (GLP-1) receptor agonists (GLP-1Ras),which both suppress glucagon secretion, have attracted increasing attention to treat T2DM (112). The gene discussed is GCG; the disease is type 2 diabetes mellitus.